Sciformix Corporation Has Been Acquired by Covance, the Drug Development Business of LabCorp (NYSE: LH)
June 13, 2018
Sciformix Corporation (“Sciformix” or “the Company”), a leading scientific process outsourcing (“SPO”) organization, has been acquired by LabCorp. The Company will become part of Covance, LabCorp’s drug development business. Financial terms of the transaction were not disclosed.
Cain Brothers served as Sciformix’s exclusive financial advisor in connection with the transaction.
Headquartered in Westborough, MA, Sciformix is a leading scientific process outsourcing (SPO) company that partners with life science organizations to provide a full range of post-commercialization services including: Safety & Risk Management, Clinical Research & Post-Approval Support, Regulatory Affairs & Regulatory Operations, Real World Evidence & Market Access, and Technology Services for over 50 clients globally. With locations in the U.S., India, Philippines, United Kingdom and Romania, and with approximately 1,100 employees, the Company leverages its domain expertise and a leading life sciences technology platform to enable better insights and outcomes on behalf of its global customer base.
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services.
For more information, please contact: